Black Diamond Therapeutics (BDTX) News
NASDAQ: BDTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BDTX news summary
We found 4 recent headlines mentioning Black Diamond Therapeutics (BDTX): 0 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. BDTX is making an outsized move today, down 5.76% at $1.31, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Black Diamond Therapeutics to Participate in Upcoming Investor Conferences", was published by GlobeNewswire on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Black Diamond Therapeutics headlines
- Black Diamond Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic…GlobeNewswire
- Black Diamond Posts Strong Silevertinib Data; FDA Supports Phase 3 Path; Shares Rise(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) reported updated Phase 2 results for Silevertinib, a treatment for non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations,…NasdaqBDTX, BRK.B
- Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate UpdateCAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic…GlobeNewswire
- Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLCWebcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ETGlobeNewswire